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TNF-alfa in the HIV-1 related activation of apoptotic pro-
cess.
Conclusions: These results indicate that HIV-1 triggers
apoptosis in osteoblasts and HOBIT cells through the gp120
interaction with cell membrane and TNF-alfa induction sug-
gesting a novel mechanism in the HIV-1 related impairment
of the bone mass structure homeostasis.
doi:10.1016/j.ijid.2008.05.608
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Objective: To compare the Tumor Necrosis Factor-alpha
(TNF-) levels in HIV infected and uninfected healthy indi-
viduals and to evaluate TNF- release in the presence of
Vitamin D3, EB 1089 and methyl prednisolone in whole blood
cell cultures of HIV infected and uninfected individuals.
Methods: Plasma TNF- estimation: Blood was collected
from healthy blood donors (n = 66) & HIV infected patients
(n = 71) after their consent. Plasmawas separated and stored
at -700C till TNF- levels were measured.
Whole Blood cell assay: TNF- release was evaluated
in whole blood cell cultures of HIV infected (n = 13) and
uninfected individuals (n = 7) with and without modulators
such as Phytohaemagglutin (PHA) and Concanavalin-A (Con-
A); Methylprednisolone sodium succinate, Vitamin D3 and
EB1089 all of which have a potential affect on TNF- release.
Cytokine assay: The TNF- levels were estimated by
sandwich ELISA using R& D systems kit.
Results: There was a wide range of values of TNF- lev-
els in individuals of both uninfected and HIV infected groups.
There was a signiﬁcant decrease in the plasma TNF- levels
in HIV infected as compared to uninfected group. Stimula-
tion of whole blood cell cultures by Con A & PHA did not
show signiﬁcant differences in the TNF- release between
uninfected and HIV infected individuals. When stimulated
whole blood cultures were incubated in the presence of
methylprednisolone, vitamin D3 and EB 1089, only methyl-
prednisolone showed signiﬁcant difference in the inhibition
pattern as compared to others.
Conclusion: There is a wide scatter of individual plasma
TNF- values in patients & normal individuals. TNF- release
in the whole blood assays of normal & HIV patients also
showed a wide variation. Methylprednisolone exerted max-
imum inhibition in TNF- release as compared to other
modulators. Clinical follow up and longitudinal studies on
TNF- levels in patients could indicate its role in the pro-
gression of HIV to AIDS.
doi:10.1016/j.ijid.2008.05.609
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Approximately 10—40% of HIV-infected patients respond-
ing to antiretroviral therapy (ART) develop immune
restoration disease (IRD). It is thought that patients experi-
ence clinical deterioration as a result of an inﬂammatory
response to intact subclinical pathogens and/or residual
antigens.
Objective: To determine the incidence and risk factors
for the development of IRD in a cohort of severely immuno-
suppressed patients during successful treatment with ART
(triple therapy) at the UMMC clinic.
Methods: Patients were monitored and clinical data char-
acterized at weeks 0, 6, 12, 24 and 48 of ART from 47
patients with age, gender, ethnicity, CD4 T-cell count and
percentage, and plasma HIV RNA.
Results: The incidence of IRD in our cohort was 27.7%,
and the commonest IRD event was an exacerbation of symp-
toms (cervical lymphadenitis, lymphadenopathy and lymph
nodes evolving into abscesses or cold abscess enlargement)
associated with pre-existing infections with Mycobacterium
tuberculosis (MTb). Having a low baseline CD4 T-cell count
and percentage was a risk factor for developing IRD. TB IRD
occurred in patients who started ART within 6 weeks of TB
treatment.
Conclusion: Patients with advanced disease initiating ART
must be closely monitored in the ﬁrst 6 months for develop-
ment of IRD. In areas where MTB is endemic, TB IRD may
occur frequently and lead to diagnostic and therapeutic
challenges.
doi:10.1016/j.ijid.2008.05.610
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Objectives: A proportion of HIV patients beginning
antiretroviral therapy (ART) develop immune restoration
disease (IRD). Immunological characteristics of IRD were
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investigated in a cohort of severely immunosuppressed HIV
patients beginning therapy at University Malaya Medical
Centre (UMMC).
Design: Peripheral Blood Mononuclear Cell (PBMC) were
collected at weeks 0, 6, 12, 24 and 48 of ART from ﬁve
patients experiencing IRD (3 with cryptococcal and 2 with
Mycobacterium tuberculosis [Mtb] disease) and eight non-
IRD controls who had begun ART with CD4 T-cell counts of
<100/L.
Methods: T cells producing interferon-gamma (IFN-)
were quantiﬁed by ELISpot assay after stimulation with
puriﬁed protein derivative (PPD), 6 kDa early-secreted
antigenic target (ESAT-6), Cryptococcus neoformans or
Cytomegalovirus (CMV) antigens. Plasma IgG antibody to
these antigens were assayed by ELISA. Proportions of
activated (HLA-DRhi) and regulatory (CD25+CD127lo and
CTLA-4+)-CD4+ T-cells were quantitated by ﬂow cytometry.
Results: IRD patients displayed elevated IFN- responses
and/or plasma IgG antibody to PPD, but none responded
to ESAT-6. Cryptococcal IRD was associated with IFN- and
antibody responses to cryptococcal antigen. Proportions of
activated and natural regulatory CD4+ T-cells (Treg) declined
on ART, but remained higher in patients than healthy con-
trols. At the time of IRD, proportions of activated CD4+
T-cells and Treg were generally elevated relative to other
patients.
Conclusions: Cryptococcal and Mtb IRD generally coin-
cided with peaks in the proportion of activated T-cells,
antigen-speciﬁc IFN- responses and reactive plasma IgG.
IRD did not reﬂect a paucity of Treg.
doi:10.1016/j.ijid.2008.05.611
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The sexual route is the main means of transmission of
the human immunodeﬁciency virus (HIV). With the increas-
ing numbers of HIV-infected women, the investigation of
particular biological features of HIV infection in the genital
tract has become more important. To evaluate HIV genital
shedding during the menstrual cycle, we collected cervico-
vaginal lavages (CVL) from 17 women, assisted at an HIV
outpatient clinic in Sa˜o Paulo, in different hormonal phases
during 2 cycles. HIV-RNA and proviral DNA shedding were
quantiﬁed using RT-PCR and a TaqMan real-time PCR assay,
respectively. In addition, patients were screened for gen-
ital coinfections and had their HIV plasma viral loads and
CD4+ cell counts assessed. Cell-free HIV-RNA and proviral
DNA shedding were found in 18.8% and 31.3% of women.
All patients who shed HIV-RNA were also shown to present
detectable proviral DNA in their CVL, including one woman
with undetectable HIV plasma viral load. No signiﬁcant dif-
ference in viral shedding was seen among menstrual cycle
phases. Six patients from the cohort, who exhibited genital
coinfections previous to admission to the study, had their HIV
genital shedding compared at time of coinfection and after
its resolution. In two of them proviral DNA shedding was
higher at the time of coinfection, caused by Streptococcus
sp and Ureaplasma sp. No cell-free HIV-RNA shedding was
detected in coinfected patients. Our results may contribute
to the understanding of HIV sexual infectivity from women
and emphasize the need for adherence to protected sexual
practices in order to avoid viral transmission.
doi:10.1016/j.ijid.2008.05.612
41.006
HIV Cervicovaginal Shedding among Postmenopausal and
Fertile Women from Sao Paulo, Brazil
K.C. Melo1, M.R. Melo2, A.C. Segurado3,∗
1 School of Medicine, University of Sao Paulo, Sao Paulo,
Brazil
2 Molecular Medicine Laboratory, Santa Casa de Sao Paulo
Medical School, Sao Paulo, Brazil
3 Department of Infectious Diseases, School of Medicine,
University of Sao Paulo, Sao Paulo, Brazil
Background: Few studies have focused on modiﬁcations
in the genital tract of postmenopausal women and their
association with HIV shedding. In this cross-sectional study
HIV-RNA shedding was compared between fertile and post-
menopausal women followed at a specialized centre in Sao
Paulo, Brazil. Correlations between viral shedding and HIV
viral loads and CD4+ lymphocyte counts were also investi-
gated.
Methods: 146 HIV-infected women [73 postmenopausal
(PM)/73 fertile(F)] were enrolled at the University of Sao
Paulo Medical School. Postmenopausal women referred a
mean duration of 8.17 years since menopause. CD4+ cell
counts were assessed by ﬂow cytometry and HIV-RNA quan-
tiﬁed in plasma and in cervicovaginal lavages (CVL) using
Cobas Amplicor HIV-1 Monitor Ultrasensitive Test. LiCl was
introduced into the CVL buffer and measured before and
after sample collection to determine CVL dilution for each
specimen.
Results: The prevalence of HIV-RNA shedding was simi-
lar in both groups (PM: 17.8%, 95% CI 9.8—28.5 vs. F: 22%,
95% CI 13.1—33.1). Likewise, mean intensity of shedding was
shown not to differ between groups (PM: 2.18log/mL, F:
2.25log/mL). Plasma viral loads were detectable in 34.2%
of postmenopausal, as compared to 42.5% of fertile women
(p = 0.395). Three patients (2 PM/1 F) exhibited HIV shed-
ding in the absence of detectable viraemia. HIV plasma viral
loads and cervicovaginal shedding were signiﬁcantly corre-
lated in both groups (PM: r = 0.658, F: r = 0.684, p < 0.01).
CD4+ cell counts were negatively correlated to HIV shedding
(PM: r =−0.250, F: r =−0.248, p < 0.05).
Conclusions: Despite changes that occur in the vaginal
mucosa of menopausal women, HIV shedding does not seem
to be signiﬁcantly inﬂuenced by this state. Plasma viral loads
and CD4+ cell counts are correlated to HIV shedding, but
these factors alone do not fully predict HIV loads in CVL,
